Anal Cancer 2025 UPDATE
Two Onc Docs
00:00
Retifanlimab Single-Agent Approval and Subsequent Lines
They note single-agent approval for IO-intolerant patients and list later-line options including Fulfox, DCF, and other immunotherapies.
Play episode from 08:59
Transcript
